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Vaccines work by eliciting an immune response and consequent immunological memory that mediates
protection from infection or disease. Recently, new methods have been developed to dissect the immune
response in experimental animals and humans, which have led to increased understanding of the molecular
mechanisms that control differentiation and maintenance of memory T and B cells. In this review we will
provide an overview of the cellular organization of immune memory and underline some of the outstanding
questions on immunological memory and how they pertain to vaccination strategies. Finally we will discuss
how we can learn about antigen design from the interrogation of our memory T and B cells—a journey from
vaccines to memory and back.Introduction
Immunological memory is the ability of the immune system to
respond with greater vigor upon re-encounter with the same
pathogen and constitutes the basis for vaccination (Ahmed
and Gray, 1996). In fact, the concept of vaccination originated
several hundred years ago from historical observations, dating
as far back as 400 B.C., that individuals that survived a disease
rarely got the same disease a second time (Finley, 1951; Plotkin
and Plotkin, 2008). The first recorded attempts at immunization
occurred in the 16th century when the process of variolation
was used to prevent smallpox (Plotkin and Plotkin, 2008). This
involved injecting smallpox pustules from an infected patient
into healthy individuals. It is remarkable that these first attempts
at immunization predate any knowledge about microbiology and
immunology. The major breakthrough in vaccination came in
1796 when Jenner used cowpox as a vaccine against smallpox.
It is worth noting that this landmark work of Jenner was also
rooted in the concept of memory because he had astutely
observed that milkmaids who had gotten cowpox were spared
the ravages of smallpox (Plotkin and Plotkin, 2008).
Vaccination remains the most effective method of preventing
infectious diseases and represents the most relevant contribu-
tion of immunology to human health (Plotkin and Plotkin, 2008;
Siegrist, 2008). The phenomenal success of vaccines against
polio, smallpox, measles, diphtheria, tetanus, rabies, etc.,
demonstrates the potential of this approach in reducing the
global burden of infectious diseases and, in the case of smallpox,
of completely eradicating a scourge that used to kill and disfigure
a substantial population of the world (Breman and Arita, 1980).
However, despite these remarkable successes there are major
challenges that still remain and there is an urgent need to
develop vaccines against important human pathogens such as
HIV, Mycobacterium tuberculosis, Plasmodium falciparum,
hepatitis C virus (HCV), respiratory syncytial virus (RSV), and
dengue virus (Houghton and Abrignani, 2005; Johnston and
Fauci, 2007; Langhorne et al., 2008; McMichael et al., 2010;
Skeiky and Sadoff, 2006; Whitehead et al., 2007). In addition,
vaccines to fight cancer and autoimmune diseases are now
a highly sought after goal and represent an exciting new areaof vaccine research and development (Larche´ and Wraith,
2005; Lollini et al., 2006; Melief and van der Burg, 2008).
In this review we will discuss how studies on immunological
memory, by defining the metrics, quality, and specificity of the
immune response, may provide a rational approach to vaccine
development. Accordingly, in the first part we will provide an
overview of the cellular organization of immune memory; in the
second part we will consider some of the outstanding questions
on immunological memory and protective immunity and how
they pertain to vaccination strategies; and in the last section
we will discuss how we can learn from our memory T and B
cells—a process of going back from memory to vaccine design.
Cellular Organization of Immunological Memory
Division of Labor among Memory Cells
Memory T and B cells are the progeny of antigen-specific naive
cells that have been clonally expanded in the course of an
immune response and survive once antigen has been eliminated.
Memory cells confer immediate protection and generate
secondary responses that are more rapid and of higher magni-
tude as compared to primary responses (Table 1). In the B cell
system, immediate protection is mediated by long-lived plasma
cells that are present in the bone marrow and secrete antibodies
in an antigen-independent fashion, thus maintaining constant
amounts in serum and body fluids (Radbruch et al., 2006); recall
responses are mediated by memory B cells that rapidly prolif-
erate and differentiate in response to antigenic stimulation
generating a burst of plasma cells and a marked but transient
elevation in serum antibodies. A similar division of labor applies
to the T cell system (Sallusto et al., 2004). Immediate protection
is conferred by circulating or tissue-resident effector memory T
(Tem) cells that survey frontline barriers and diseased tissues
for incoming pathogens and display immediate effector function
upon antigen recognition (Masopust et al., 2001; Sallusto et al.,
2004); recall responses are mediated by central memory T
(Tcm) cells that patrol the T cell areas of secondary lymphoid
tissues where they can rapidly proliferate in response to antigens
presented by dendritic cells (DCs). This division of labor has
implications for vaccination strategies because protection fromImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 451
Table 1. First and Second Lines of Adaptive Immunity against Pathogens
First Line Second Line
Central players antibody (IgA and IgG); Tem (tissue-resident
memory T cells)
memory B cells; Tcm
Localization of the central players sites of pathogen entry (gut, genital tract,
respiratory tract, blood, etc.)
lymphoid tissues
Rapid protection yes, immediately delayed; memory cells in lympoid tissues respond
rapidly compared to naive cells; however, their
capacity for immediate protection is limited because of
the delay in reaching sites of infection
Recall response minimal to moderate substantial clonal expansion; differentiation into
effector and plasma cells; migration into multiple
tissues including sites of infection
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depending on the nature of the pathogen and the size and route
of challenge. For instance, preformed antibodies and long-lived
plasma cells are required to neutralize toxins or prevent infection
by an incoming virus, whereas recall responses mediated by
Tcm cells and memory B cells may be sufficient to protect
against viruses with long incubation time (Plotkin et al., 2008).
From Naive to Memory T Cells
The quality and amount of memory T cells is set during antigen-
driven primary immune responses, which are initiated in the T cell
areas of secondary lymphoid organs where rare antigen-specific
naive T cells are stimulated by antigen presented by activated
DCs. Pathogens can activate DCs by triggering multiple innate
receptors either directly via pathogen-associated molecular
patterns (PAMPS) or indirectly via danger-associated molecular
patterns (DAMPS) leading to enhanced antigen presentation,
costimulation, and production of polarizing cytokines (Iwasaki
and Medzhitov, 2010). It is the nature and combination of the
innate receptors triggered on DCs that determine their capacity
to imprint different fates on proliferating T cells (Reiner et al.,
2007). In response to certain viruses and intracellular pathogens,
DCs produce interleukin-12 (IL-12), which promotes differentia-
tion to T helper 1 (Th1) cells capable of producing interferon-g
(IFN-g), which is effective against such pathogens (Macatonia
et al., 1995). Likewise, in response to fungi or certain bacteria,
DCs and monocytes produce IL-1b, IL-6, and IL-23 that drive
differentiation of Th17 cells that through secretion of IL-17 and
recruitment of neutrophils mediate protection against extracel-
lular pathogens (Acosta-Rodriguez et al., 2007). The protective
nature of these polarized responses is underlined by studies of
human immunodeficiencies, where patients with defective Th1
or Th17 cell responses suffer frommycobacterial or fungal infec-
tions, respectively (Ma et al., 2008; Milner et al., 2008). A more
complex pathway triggered by helminths or allergens and
involving epithelial cells and IL-4-producing innate or natural
helper cells appears to control the induction of Th2 cells that
produce IL-4, IL-5, and IL-13 and mediate protection or allergy
(Coffman, 2010). Other effector (and memory) T helper cell
subsets have been recently characterized in mice and humans,
such as Th9 (Veldhoen et al., 2008) and Th22 (Duhen et al.,
2009; Trifari et al., 2009) cells, which may be involved in allergy
and skin defense, respectively. CD4+ T cells not only act directly
to promote different types of inflammatory responses in tissues,
but also play an essential role in B cell and CD8+ T cell452 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.responses. A dedicated subset of follicular helper (Tfh) T cells
is required for induction of germinal center reactions that leads
to differentiation of memory B cells and long-lived plasma cells
secreting high-affinity antibodies of switched isotypes (Vinuesa
et al., 2005). Tfh cells produce IL-21 and their differentiation is
dependent on the transcription factor Bcl-6 (Kassiotis and
O’Garra, 2009) and a high-avidity interaction with antigen-
specific B cells (Fazilleau et al., 2009; Qi et al., 2008). T helper
cells can also promote DC maturation via CD40L-CD40 interac-
tion and in this way help the generation of effector and memory
CD8+ T cells against poorly immunogenic antigens such as
protein antigens (Lanzavecchia, 1998). In the context of vaccine
design, more detailed studies should aim at defining on the one
hand the pattern of expression of innate receptors in mice and
humans, on the other the cytokines and cues that drive differen-
tiation of different effector T cell subsets.
The quality of the T cell response is profoundly influenced not
only by the PAMPs and DAMPs but also by the nature of the DCs
that present antigen and by the tissue microenvironment in
which the T cell response takes place. A distinct subset of mouse
CD8a DCs can process and present exogenous antigens on
MHC class I molecules and crossprime cytotoxic T lymphocyte
(CTL) responses (Heath and Carbone, 2009), and DCs with
similar properties have been recently described in humans (Villa-
dangos and Shortman, 2010). Gut- and skin-derived DCs can
imprint the expression of skin- and gut-homing receptors, such
as CCR9 or CCR10, in differentiating T cells (Sigmundsdottir
and Butcher, 2008). Monocytes represent an abundant and
heterogeneous population of circulating cells that can be rapidly
recruited to sites of inflammation and immune response where
they differentiate into DCs (Auffray et al., 2009). The importance
of studies addressing the role of different DC and monocyte
subsets in T cell responses cannot be overemphasized in view
of the possibility of targeting antigens and vaccines to different
cell types in vivo (Bonifaz et al., 2004; Kamphorst et al., 2010;
Palucka et al., 2010, this issue).
B Cells and Antibody Responses
The B cell response to protein antigens is a highly orchestrated
process that is initiated at the boundary between T and B cell
areas where T cells primed by antigen-presenting DCs
encounter specific B cells that have captured and processed
native antigen relayed by macrophages lining the subcapsular
sinus (Phan et al., 2009). The antigen-specific T-B cell interaction
leads to a rapid expansion and differentiation of B cells into
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This extrafollicular response is followed by the formation of
germinal center reaction where Tfh cells and antigen trapped
on follicular dendritic cell (FDC) networks drive proliferation, iso-
type switch, and affinity maturation of antigen-specific B cells
leading to the generation of memory B cells and long-lived
plasma cells that produce high-affinity somatically mutated anti-
bodies of switched isotypes (Allen et al., 2007). The duration of
the germinal center reaction may vary depending on the nature
of the antigen andmay last for several weeks ormonths, implying
that high-affinity antibodies and memory cells can be generated
well after elimination of the pathogen (Dogan et al., 2009).
Unlike protein antigens that elicit T cell-dependent B cell
responses, bacterial polysaccharides trigger T cell-independent
B cell responses that result in the generation of short-lived
plasma cells without memory cells. Repeated stimulations with
polysaccharides can lead to progressively decreased responses
and eventually exhaust specific B cells (Pollard et al., 2009). In
contrast, the same polysaccharides conjugated to protein anti-
gens elicit a T cell-dependent B cell response and memory B
cells that can be effectively boosted by the same glycoconju-
gate. This approach has been successfully used to develop
highly effective conjugated vaccines against pneumococcus
and meningococcus (Plotkin and Plotkin, 2008).
In humans a large fraction of circulating B cells are IgM+ and
carry somatically mutated Ig genes. It is currently unclear whether
these cells represent a circulating equivalent of mouse marginal
zone B cells that respond to blood-borne pathogens or a popula-
tion of bona fide memory cells (Seifert and Ku¨ppers, 2009; Weill
et al., 2009). Recently, by using a mouse model of AID (activa-
tion-induced cytidine deaminase)-dependent cell labeling, it was
shown that memory B cells appear in the IgM+ and IgG1+ subsets
found both in germinal centers and outside of B cell follicles. After
challenge, the IgG1+ subset differentiated into plasma cells,
whereas the IgM+ subset reinitiated a germinal center reaction,
suggesting a division of labor similar to that described for Tem
andTcmcells (Doganetal., 2009).Thesefindings,when translated
into the human system, will have important implication for moni-
toring vaccination by dissecting immediate antibody responses
from germinal center-dependent secondary responses.
Maintenance of Memory Cells
Only a small fraction of the expanded cells present at the peak of
the immune response survive as memory cells (Harty and
Badovinac, 2008; Kaech andWherry, 2007). In mice, the precur-
sors of memory CD8+ T cells could be identified as IL-7Rhi cells,
whereas the more abundant KLRG1hi (killer cell lectin-like
receptor G1) cells were shown to represent short-lived effector
cells (Joshi et al., 2007; Kaech et al., 2003; Sarkar et al., 2008).
It appears that the ratio between effectors and memory precur-
sors is set by differential expression of transcription factors, such
as T-bet and Eomesodermin, which in turn is dependent on the
strength of stimulation by antigen, cytokines, and Wnt signaling
(Gattinoni et al., 2009; Intlekofer et al., 2005). With methods for
analyzing the progeny of single cells, it has been recently shown
that within a single clone T cells can adopt multiple fates,
including different types of effector and memory cells, and that
individual naive T cells expressing high- or low-avidity T cell
receptor (TCR) yield both effector and memory T cells (Gerlach
et al., 2010; Stemberger et al., 2007).Memory T and B cells as well as long-lived plasma cells can be
maintained at relatively constant numbers in the absence of the
eliciting antigen for virtually a lifetime. Their survival is dependent
on exogenous cytokines that are available in distinct niches and
determine the size of the memory pool. For CD4+ and CD8+
memory T cells, the survival cytokines are IL-7 and IL-15, which
maintain these cells in a state of slow but continuous proliferation
(Surh and Sprent, 2008). Memory B cells also divide at low rate
but a survival cytokine has not yet been defined although it has
been shown that an intact B cell receptor (BCR) and phospholi-
pase Cg2 are required for their long-termmaintenance and func-
tion (Hikida et al., 2009). In contrast, long-lived plasma cells
survive without dividing in bone marrow niches organized by
stromal cells that provide, in association with other cells, survival
cytokines such as IL-6 and APRIL (Radbruch et al., 2006). Unlike
memory T cells that elaborate their cytokines only in response to
antigenic stimulation, long-lived plasma cells continually
produce antibodies, thus maintaining serum levels constant.
The bone marrow also contains memory CD4+ and CD8+
T cells that may recirculate, as well as a recently described pop-
ulation of sessile resting memory T cells that occupies a distinct
niche in contact with IL-7-producing stromal cells (Tokoyoda
et al., 2009).
The fact that terminally differentiated effector memory cells
such as Tem and plasma cells have reduced or no proliferative
and reconstitution capacity led to the hypothesis that long-
term maintenance of memory cells would be dependent on
cells that retain proliferative capacity, such as Tcm and
memory B cells or even on a specialized subset of ‘‘memory
stem cells’’ (Lanzavecchia and Sallusto, 2002; Fearon et al.,
2001). In the case of T cells, this model is supported by the
findings that long-term reconstitution capacity is characteristic
of Tcm rather than Tem cells (Wherry et al., 2003) and by the
prospective isolation of a putative memory stem cell (Gattinoni
et al., 2009; Turtle et al., 2009). Recent studies identified
signaling pathways that appear to be involved in the differenti-
ation of memory stem cells as well as drugs that favor the
generation of Tcm cells (Araki et al., 2009; Gattinoni et al.,
2009; Pearce et al., 2009).
There has been much debate on the role of antigen in main-
taining memory but it is now clear from carefully done cell trans-
fer experiments employing a variety of model systems that both
memory T and B cells can persist in the absence of antigen
(Gray, 2002; Hou et al., 1994; Lau et al., 1994; Zinkernagel,
2003). These findings were further extended by showing that
memory T cells can persist even in the absence of the restricting
MHC molecules (Murali-Krishna et al., 1999; Swain et al., 1999).
However, antigen persistence in GC plays an important role in
selection and maturation of the B cell response and there are
data suggesting that antigen-antibody complexes can persist
on FDCs for extended periods of time and that this antigen
may play a role in shaping the B cell repertoire (Chen et al.,
1978; Tew et al., 1980). Interestingly, sustained high amounts
of soluble antigens can often lead to induction of tolerance or
exhaustion both in T and B cells. In the case of certain chronic
viral infections, antigen-specific T and B cells express a variety
of inhibitory receptors that result in functional exhaustion of
these cells (Barber et al., 2006; Virgin et al., 2009; Wherry
et al., 2007).Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 453
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During the past decade, there has been considerable interest in
defining the global gene expression profiles of memory T and B
cells (Haining and Wherry, 2010; Kaech and Wherry, 2007; Staal
and Clevers, 2005). This approach has been highly informative
because it provides an unbiased look at all the genes that are
up- or downregulated during memory differentiation. Particularly
valuable have been studies that have performed an integrative
genomic analysis of antigen-specific T cells as they progress
from the naive to effector to memory transition (Kaech et al.,
2002). Such longitudinal studies have not only identified key
genes (transcription factors, survival molecules, cytokine and
chemokine receptors, homing and signaling molecules, etc.)
that are differentially expressed between naive and memory
T cells but have also provided insights into mechanisms of
memory formation and in defining the signatures of effector
and memory T cells. Gene profiling studies also provided
insights into themechanisms of T cell dysfunction during chronic
infections and identified key inhibitory receptors that are ex-
pressed by the exhausted virus-specific T cells (Barber et al.,
2006; Wherry et al., 2007).
Naive B cells may differentiate directly into short-lived
plasma cells, or may pass through the germinal center reaction
to become either memory B cells or long-lived plasma cells.
The gene expression patterns associated with these transitions
have been analyzed by several groups via DNA microarrays
(Good-Jacobson and Shlomchik, 2010). The differentiation
of a naive B cell to either a germinal center B cell or a plasma
cell is accompanied by major changes in gene regulation,
driven by the master transcription factors Bcl-6 and blimp-1.
Less is known about the gene expression differences that
distinguish short- from long-lived plasma cells. The gene
expression signatures of long-lived plasma cells isolated from
human bone marrow has recently been compared with that of
short-lived plasma cells derived from in vitro stimulation of
memory B cells (Jourdan et al., 2009). This study showed
that bone marrow plasma cells display a reduced expression
of the proapoptic molecule Fas as well as downregulation of
molecules involved in lymphocyte trafficking such as CD62L
and S1PR1. Thus, it appears that bone marrow plasma cells
display resistance to apoptosis and a reduced ability to traffic
to other anatomic sites. More detailed studies defining the
signatures of long-lived versus short-lived plasma cells will be
useful in developing vaccines that induce long-term humoral
immunity.Outstanding Questions on Immunological Memory
and Vaccination
We will now consider some key questions about memory and
protective immunity and how they pertain to developing the
next generation of vaccines. Our remarkable successes in
vaccines have come mostly against acute infections caused
by invariant pathogens (Plotkin et al., 2008). However, we lack
effective vaccines against pathogens that are highly variable
and/or cause persistent and latent infections such as HIV,
HCV, and M. tuberculosis (Houghton and Abrignani, 2005;
Johnston and Fauci, 2007; McMichael et al., 2010; Skeiky and
Sadoff, 2006). It has also proven difficult to develop successful454 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.vaccines against acute infections such as RSV and malaria
where the natural infection itself does not result in complete
protection against reinfection—in this case the vaccine has to
trump nature (Langhorne et al., 2008). Developing effective
vaccines against these important human diseases presents
a unique set of challenges for each pathogen and there are
reviews in this issue of Immunity that deal specifically with
HIV, TB, and malaria vaccines (McElrath and Haynes, 2010;
Kaufmann, 2010; Good and Doolan, 2010). However, there
are also fundamental concepts of immune memory and vacci-
nation that cut across different pathogens and we will now
consider a few of these key issues starting with a brief general
discussion on protective immunity and correlates of vaccine
efficacy.
Protective Immunity and Correlates of Vaccine Efficacy
There has been considerable interest and debate in determining
the relative importance of T and B cell responses in protective
immunity (Ahmed and Gray, 1996). When examining this issue,
one must remember that antibodies and T cells have evolved
to perform distinct functions. The business of antibodies is to
deal with the microbe itself (i.e., free virus particles, bacteria,
and parasites) and that of T cells is to deal with infected cells.
Because T cells can recognize microbial antigens only in associ-
ation with host MHC molecules, the free virus particles or
bacteria are invisible to them. Thus, antibody provides our only
specific defense against free microbial organisms, and the
importance of preexisting antibody in protective immunity
against infectious diseases cannot be overemphasized. In fact,
antibody is likely to be the sole mechanism of protective immu-
nity against bacteria and parasites that have an exclusively
extracellular lifestyle. In these situations, it is relatively easy to
determine the correlates of vaccine efficacy based on the levels
of serum antibody against the pathogen or the toxin (Siegrist,
2008). However, the equation begins to change for viruses and
for bacteria and parasites that can survive or replicate intracellu-
larly. Although antibody again provides the first line of defense
against such infections and antibody levels are used as the
correlates of vaccine efficacy for several viral vaccines such as
influenza virus and yellow fever virus (Siegrist, 2008), there are
often situations where not all of the inoculum is neutralized or
opsonized by the preexisting antibody. This is where the
T cells come into play by either killing the infected cell and/or
releasing cytokines that inhibit growth of the microbe or impair
the ability of the pathogen to survive inside the cell. For example,
T cell immunity is a more accurate correlate for efficacy of the
zoster vaccine (Levin, 2008).
Defining correlates of vaccine efficacy against pathogens that
vary is going to be much more challenging because the mecha-
nism of protective immunity may vary depending upon the viral
strain that the individual is exposed to. It is likely that newer
approaches will be needed to define correlates and that the
traditional method of using a single parameter to determine
vaccine efficacy is simply not going to work with our more diffi-
cult vaccines. There is now considerable excitement at the pros-
pect of using systems biology approaches to define correlates of
vaccine efficacy (see review by Pulendran et al., 2010, in this
issue). However, even this by itself may not be sufficient and
perhaps the solution lies in combining the systems biology
approaches with more novel methods of assessing not only
AB
Figure 1. Using the Principles of Memory T
Cell Differentiation to Determine the
Optimal Time for Boosting
(A) After primary vaccination, naive T cells prolif-
erate and differentiate into effector cells. The
majority of these effectors undergo apoptosis but
a subset further differentiates to form the pool of
long-livedmemory cells. Thismodel of progressive
memory T cell differentiation is characterized by
a gradual acquisition of memory T cell properties
such as the ability to make effective proliferative
responses upon re-encounter with antigen.
(B) Based on this memory differentiation program,
the optimal time for boosting is during the late
stages of the effector to memory transition, and
therefore an interval of 2–3 months is recommen-
ded between the prime and the boost.
Immunity
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responses.
Optimizing Prime-Boost Regimens
A multitude of expression vectors (bacterial, viral, DNA) have
been developed during the past two decades, and considerable
effort has gone into optimizing their use as vaccine vectors (Liu,
2010, this issue). Several studies have shown that boosting
with a different vector carrying the same antigen is better
for enhancing immune responses compared to boosting with
the homologous vector. Such heterologous prime-boost ap-
proaches are now widely used in efforts to develop vaccines
against HIV, HCV, malaria, and TB (see articles in this issue).
Although promising results have been obtained with various
heterologous prime-boost vaccines, some fundamental ques-
tions remain unanswered. Here we will briefly address two key
questions: first, what is the optimal time for boosting, and
second, what is the effect of repeated booster shots on the
quality of the immune response?
In determining the interval between the first immunization and
the booster shot, it is important to consider the differentiation
pathways of memory B and T cells. Memory T cells with high
proliferative potential do not form until several weeks after the
first immunization, so as a general rule it is better to have an
interval of at least 2–3 months between the prime and the boost
(Figure 1). Boosting too early will give suboptimal responses.
Similar rules apply for boosting antibody responses because
memory B cells have to go through the germinal center reaction
and take several months to develop (Crotty et al., 2010). Recent
studies have shown that repeated boosting can drive memory
T cells toward terminal differentiation (Masopust et al., 2006;Immunity 33,Wirth et al., 2010). This is good for gener-
ating effector memory T cells and also for
driving cells to the mucosa but runs the
risk of depleting the population of central
memory cells (Figure 2). However, if the
repeated booster shots recruit only a
subset of the previously generated mem-
ory cells, then this will result in a heterog-
enous population of memory T cells at
various stages of differentiation (Figure 2).
This could end up providing the right
balance of Tcm and Tem cells. In sum-
mary, by using our understanding ofmemory T and B cell differentiation, it should be possible to opti-
mize prime-boost strategies.
Modulating the Quality of Memory T Cells
In order to develop successful vaccines against pathogens such
as HIV, HCV, malaria, etc., it will be essential for the vaccine not
only to induce neutralizing antibody responses but also to
generate highly effective T cell immunity. Considerable effort
has gone into developing vaccine regimens that will induce
high frequencies of memory T cells, but there has been minimal
emphasis on developing strategies to improve the functional
qualities of the vaccine-induced memory T cells. However, there
is now an appreciation that by targeting appropriate innate
receptors on DCs, it is possible to modulate the functional qual-
ities of memory cells (Coffman et al., 2010, this issue).
Recent studies have identified an additional approach by
means of drugs that directly act on T cells to regulate memory
differentiation (Araki et al., 2009; Pearce et al., 2009; Rao et al.,
2010). These studies showed that mammalian target of rapamy-
cin (mTOR) is a major regulator of memory CD8+ T cell differen-
tiation and that memory T cell qualities can be manipulated by
regulating the mTOR pathway. In vivo administration of rapamy-
cin, a specific inhibitor ofmTOR, into vaccinated or infectedmice
markedly changed the fate of antigen-specific CD8+ T cells.
Rapamycin treatment during the T cell expansion phase
increased the quantity of memory CD8+ T cells by promoting
the generation of memory precursors that survive and differen-
tiate into long-lived memory cells. This treatment resulted in
a similar number of antigen-specific effector CD8+ T cells at
the peak of the clonal expansion compared to untreated mice
but reduced the apoptotic cell death during contraction phase.October 29, 2010 ª2010 Elsevier Inc. 455
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Figure 2. Repeated Immunizations Drive Memory T Cells toward
Terminal Differentiation: Implications for Memory Cell
Heterogeneity and Protective Immunity
(A) Repetitive antigen encounter results in memory T cells with more effector-
like properties and with preferential location in nonlymphoid tissues but with
reduced proliferative potential.
(B) If allmemoryTcellsare recruited into theresponseaftereachboostershot, then
the entire pool of memory T cells would be driven toward terminal differentiation.
456 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.
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tion phase accelerated the effector to memory cell transition
and improved the quality of memory CD8+ T cells. Thus, target-
ing the mTOR pathway can enhance not only the magnitude but
also the quality of memory CD8+ T cells (Figure 3).
Using drugs that modulate memory differentiation is an inter-
esting new approach to enhance vaccine-mediated immunity.
Because rapamycin has historically been used as an ‘‘immuno-
suppressive’’ drug, there will be obvious safety concerns about
using this drug as a vaccine adjuvant. However, it should be
possible to identify safer drugs that target the mTOR pathway
as potential adjuvants to enhance the functional qualities of
memory T cells.
HowManyMemory Cells CanWeAccommodate—Issues
of Competition and Space
One of the more fascinating things about the immune system is
the ability of lymphocytes to sense their numbers (Takada and
Jameson, 2009). This homeostatic regulation is quite cell
specific; B cells sense each other and not T cells and there is
also specificity in the counting of CD4+ versus CD8+ T cells.
For example, if CD4+ T cells are depleted, then there is a selective
expansion of CD4+ T cells and not CD8+ T cells to fill up the
compartment, and vice versa upon reduction of CD8+ T cells.
The mechanism of this sensing is not known but the ability of
the immune system to count has important implications for
vaccination. The conventional wisdom is that the size of the
immune system including the number of memory cells is fixed
and that as new memory cells are generated upon infection or
vaccination, there must be an erosion of pre-existing memory
cells to make room for the new ones (Freitas and Rocha, 2000;
Goldrath, 2002; Welsh et al., 2010). In principle this is correct
but it is not known how fixed this ceiling is and how much flexi-
bility exists in accommodating newmemory cells. A recent study
has addressed this critical issue and shown that the size of the
total memory CD8+ T cell pool in mice can almost double to
accommodate new cells with minimal attrition of pre-existing
memory cells (Vezys et al., 2009). It is interesting that this
increase occurred almost exclusively in effector memory
T cells, suggesting that this memory T cell subset adapts in the
host according to immunological experience. In this context, it
is worth noting that large numbers of human cytomegalovirus
(HCMV)- and Epstein-Barr virus (EBV)-specific effector memory
CD8+ T cells accumulate in humans over time (Klenerman and
Hill, 2005). In some instances, this increase is so striking that
T cells specific to a single HCMV epitope can account for up to
20% of the total CD8+ T cell response.
It is well documented from studies in both mice and humans
that the percentage of naive T cells declines with age whereas
the percentage of memory T cells increases (Linton and Dorsh-
kind, 2004; Nikolich-Zugich, 2008). It is assumed that this
reversal in the ratio of naive versus memory T cells is entirely
due to loss of naive T cells reflecting decreased thymic output
as a function of age. However, it has not been rigorously ruled
out that this observed change in the ratio is also due to an(C) If only some of the memory T cells are activated upon subsequent booster
immunizations, then one would end up with a heterogenous pool of memory
T cells with both effector-like cells at mucosal sites and also memory cells
with proliferative capacity.
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Figure 3. Using Drugs to Modulate Memory CD8+ T Cell
Differentiation
(A) Antigen-specific CD8+ T cell responses after an acute infection or vaccina-
tion. During the expansion phase, naive CD8+ T cells proliferate and then
become effector cells. After clearance of the pathogen, 90% to 95% of the
effector T cells die during a contraction phase. The surviving 5%–10% of the
antigen-specific T cells become the memory population.
(B) Without rapamycin treatment.
(C) Rapamycin improves both quality and quantity of memory CD8+ T cells.
Rapamycin treatment increases memory precursor effector cells that survive
during the contraction phase and also improves quality of memory T cells by
accelerating effector to memory T cell formation.
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immunological experience over time. This issue needs to be
addressed in detail by quantitating memory T cell numbers
in lymphoid and nonlymphoid tissues via murine as well as
nonhuman primate models. Another important question that
deserves more attention is to determine whether there is any
sensing of numbers between naive and memory T cells. In other
words, does our immune system count total numbers of T cells
irrespective of whether they are naive or memory or are naive
andmemory T cell numbers regulated independently? An under-
standing of these issues has significant implications for
designing vaccination approaches.
The B cell system is also under homeostatic control and there
aremechanisms for regulating naive andmemory B cell numbers
as well as total immunoglobulin levels in the serum (Nimmerjahn
and Ravetch, 2008; Sanz et al., 2008). A better understanding of
the underlying regulatory mechanisms is needed. In particular,
the issue of plasma cell homeostasis is critical for vaccine-induced protective immunity. Vaccine-induced antibodies can
be maintained in the serum for extended periods by long-lived
plasma cells that reside in the bone marrow and constitutively
produce antibodies in the absence of antigen (Amanna et al.,
2007; Manz et al., 1997; Slifka et al., 1998). It is believed that
the bone marrow environment is particularly conducive for
providing the necessary survival signals for plasma cells (Manz
et al., 1997; O’Connor et al., 2004). It is important to determine
how competition for these survival niches in the bone marrow
impacts vaccine-induced immunity. A critical question is how
many plasma cells can the bone marrow accommodate? Do
certain types of plasma cells compete better for these survival
niches? If so, what are the defining characteristics of these cells?
How can such plasma cells be generated? Answers to these
questions will provide a rational approach to developing
vaccines that induce long-term antibody responses.
Importance of Mucosal versus Systemic Immunity
The immune system has evolved two lines of defense against
pathogens (Table 1). The first line of defense consists of pre-
formed mucosal antibody (IgA and IgG) and effector memory
T cells that are present at the portals of pathogen entry. In addi-
tion, serum antibody also provides an important first line of
defense against pathogens that initiate infection through the
blood. The second line of defense consists of memory T and B
cells present in lymphoid tissues; these cells proliferate and
differentiate into effector cells and migrate to sites of infection.
It should be noted that memory cells in lymphoid tissues also
elaborate effector functions rapidly (much faster than naive
cells), but their importance in immediate protection is limited
because of the delay in reaching sites of infection. Consequently,
the most critical difference between Tcm and Tem cells is not so
much the speed at which they become effectors but their actual
anatomic location. The inability of Tcm cells to provide imme-
diate protection at mucosal sites is compensated by their ability
to proliferate and generate a large pool of effector cells that are
critical for limiting the spread of infection and for eventual clear-
ance of the pathogen. Thus, an ideal vaccine should induce both
mucosal and systemic immunity to provide both the first and
second line of defense against infection and disease. However,
for ‘‘hit and run’’ pathogens that infect mucosal sites and cause
clinical symptoms within 24–48 hr (e.g., rotavirus, norovirus,
enteric bacteria, etc.), it is essential to have effective mucosal
immunity. This first line of defense is also important for viruses
like HIV that can establish a latent infection if initial acquisition
is not blocked.
Considerable progress has been made in identifying homing
molecules on T and B cells that are utilized for tissue entry
(Lefrancois and Puddington, 2006). Of particular interest for
mucosal immunity are homing receptors that lymphocytes use
for migration to the gut, genital tract, and respiratory tract—three
major sites of pathogen entry. An important question that is not
well understood is how these receptors are imprinted on acti-
vated T and B cells and how this knowledge can be harnessed
to develop vaccines that will induce effective mucosal immunity.
Several studies have shown that expression of specific homing
receptors is coupled to the location of activation; for example,
priming of T cells in mesenteric lymph nodes induces expression
of a4b7 that is needed for migration to the gut whereas priming
within inguinal lymph nodes induces expression of skin-homingImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 457
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consistent with the observation that mucosal vaccines or infec-
tions are best for inducing T and B cell responses at the mucosa
(Plotkin et al., 2008).
There are many examples of systemic infections inducing
good mucosal immunity and also of some parenterally given
vaccines eliciting mucosal responses (Plotkin et al., 2008). A
recent study has provided a potential explanation for these
observations by showing that priming of CD8+ T cells in the
spleen results in a promiscuous homing program that can drive
cells to the intestinal mucosa (Masopust et al., 2010). The spleen
is a central lymphoid organ and is not directly associated with
any particular body surface. Thus, it makes teleological sense
that T cells activated in the spleen have a promiscuous homing
program so they can sample multiple tissues for infection. Inter-
estingly, expression of the gut homing receptors was very tran-
sient and only the early effector T cells in the spleen could
migrate to the gut, showing that there is only a small window
of opportunity for seeding the mucosa. What happens to the
T cells after they migrate to the gut? Several studies have now
shown that these T cells don’t recirculate with memory cells in
the blood or in other tissues and also end up undergoing a unique
differentiation program that is driven by the environment of the
tissue (Jameson and Masopust, 2009).
An important difference between systemic and mucosal
immunity is the duration of memory. As described earlier, it is
well documented that systemic memory persists for extended
periods in both experimental animals and in humans; this is
true not only for memory T and B cells but also for antibody levels
in the serum that are maintained by long-lived plasma cells in the
bone marrow. In contrast, the duration of mucosal immunity is
relatively short lived. The underlying mechanisms of this waning
memory at mucosal sites are not well understood and this
remains one of the most challenging questions in vaccinology.
Many critical issues need to be addressed: Do effector memory
T cells in the mucosa turn over and replenish their numbers? If
so, is this mediated by cytokines or by periodic re-exposure to
antigen?What is the intermitotic lifespan of these tissue-resident
memory T cells and what are the molecules necessary for their
survival? What is the lifespan of memory B cells and plasma cells
at mucosal sites? Do mucosal plasma cells get the necessary
survival signals and niches that are present in the bone marrow?
A recent study has suggested that there is attrition of previously
induced immune responses in the gut because of competition by
ongoing responses being continuously generated by the com-
mensal flora (Hapfelmeier et al., 2010). Answers to these above
questions and others are needed to understand how memory
is regulated at the mucosa and to design effective vaccine strat-
egies for eliciting long-term mucosal immunity (Jameson and
Masopust, 2009).
From Immunological Memory to Vaccine Design:
Analytic Vaccinology
As mentioned in the previous section, our successes in vaccines
have mostly come against invariant pathogens that cause acute
infections followed by long-term protective immunity. However,
there are several caseswhere the primary infection does not lead
to protective immunity. This is the case of variable pathogens
such as dengue or influenza viruses where memory elicited by458 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.the natural infection protects from the homologous virus but
not from viruses of a different serotypes (Green and Rothman,
2006), whereas in the case of HIV-1, a rapid diversification of
the transmitted virus makes the immune response ineffective
(Johnston and Fauci, 2007; McMichael et al., 2010; Moir and
Fauci, 2009). For other pathogens such as RSV, the clearance
of infection is not followed by protective memory because rein-
fection with the same virus can occur multiple times, although
with decreased severity of illness. Finally, other pathogens
such as HCMV, EBV, or M. tuberculosis are not eliminated by
the immune response and establish a life-long carrier state
where an equilibrium is reached between the host immune
response and the pathogen that persists in a latent or dormant
state (Reddehase, 2002; Sacchettini et al., 2008). The life-long
carrier state poses a risk of widespread infections when the
individual becomes immunosuppressed or immunodeficient. In
addition, HCMV can superinfect an already immune donor and
does so by evading the CD8+ T cells response, a process that
complicates the development of preventive vaccines (Hansen
et al., 2010).
Can the analysis of humanmemory cells provide novel insights
into developing vaccines against pathogens that induce partially
protective, nonprotective, or nonsterilizing immunity? Recent
studies suggest that it is possible to leverage on the analysis of
the specificity and class of human memory B and T cells to iden-
tify conserved epitopes and protective effector mechanisms that
represent a rational basis for vaccine design. Below we discuss
some methodological and technical approaches that facilitate
this process that we define as ‘‘analytic vaccinology’’ (Figure 4).
Interrogation of Memory B Cells and Isolation
of Monoclonal Antibodies
The concept that cross-reactive protective antigens could be
identified by studying the antibody response was initially pro-
posed in the context of HIV vaccine design (Burton, 2002). The
idea is to identify through the isolation of broadly neutralizing
antibodies conserved epitopes and then produce immunogens
that contain such epitopes in an immunodominant form. This
approach offers the advantage of focusing the immune response
to the most conserved epitopes while avoiding a response to the
most variable sites.
For many years the isolation of monoclonal antibodies
represented the rate-limiting step in the analysis of the human
antibody response and the identification of target antigens and
conserved epitopes. In the last 5 years, several methods have
become available to isolate with high-efficiency human mono-
clonal antibodies from memory B cells and plasma cells. These
approaches are based on immortalization of total memory B cells
followed by selectionwith functional assays (Traggiai et al., 2004)
or by isolation of antigen-binding memory B cells or of total
plasma cells followed by rescue of the specific antibodies by
single-cell PCR and expression in heterologous systems (Scheid
et al., 2009; Wrammert et al., 2008). With these methods it has
become possible to interrogate the whole repertoire of anti-
bodies made during an immune response or maintained in the
memory compartment. These approaches have already pro-
vided exciting resultswith the identification of potent and broadly
neutralizing antibodies against a variety of human pathogens.
A common theme emerging from these novel studies is that
broadly neutralizing antibodies do exist, but may be extremely
AB
Figure 4. The Use of High Throughput
Cellular Screens to Inform Vaccine Design
(A) Memory B and T cells can be isolated accord-
ing to the expression of surface markers and
cultured in limiting dilution conditions to assess
specificity, phenotype, and function of individual
cells. Specific antibodies can be retrieved by
memory B cell immortalization or by amplification
of the V region genes from single cells. T cell
libraries can be screened in an iterative fashion
to determine fine specificity and to isolate T cell
clones.
(B) Naive T cells stimulated in vitro with monocytes
or DCs and whole pathogens recapitulate the
phenotype of ex vivo isolated memory T cells.
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infected individuals has led to the identification of two donors
from whom novel potent and broadly neutralizing monoclonal
antibodies were isolated. These antibodies identify highly con-
served epitopes in the CD4 binding site (Wu et al., 2010) as well
as conformational epitopes present in the gp160 trimer (Walker
et al., 2009). Another relevant example is the selection in some
individuals of memory B cells that make antibodies that broadly
neutralize influenza viruses (Corti et al., 2010; Ekiert et al.,
2009). These antibodies are directed against conserved epitopes
in the stem region of the influenza virus hemagglutinin protein
and, although less potent than classical neutralizing antibodies
directed against the globular head, can neutralize in vitro and
in vivo viruses belonging to different subtypes. Based on this
notion, a headless hemagglutinin vaccine has been produced
and has been shown to confer broad protection in an animal
model (Steel et al., 2010). Human monoclonal antibodies with
very high neutralizing activity against HCMV have been isolated
from selected donors and used to map conformational epitopes
on a pentameric complex that represents a candidate subunit
vaccine (Macagno et al., 2009). The human antibody response
to dengue virus has been dissected through the analysis of
monoclonal antibodies, revealing basic mechanisms of neutrali-
zation and infection enhancement (Beltramello et al., 2010;
Dejnirattisai et al., 2010). Finally, the analysis of a large number
of human monoclonal antibodies to HIV revealed a role for poly-
reactivity in increasing the apparent affinity of HIV antibodies
through heteroligation, revealing a new mechanism for the
production of antibodies against pathogens displaying low-
density epitopes (Mouquet et al., 2010).
Besides their use for vaccine design, human monoclonal
antibodies can find a direct application for passive vaccination,
a prophylactic and therapeutic approach that was developed
more than one hundred years ago and which has fallen short
because of the limited availability of immune sera (Casadevall
et al., 2004). To date only one humanized monoclonal antibody
has been approved for prevention of RSV infection in newborns
but several fully human antibodies are at different stages of
development for prevention and treatment of various pathogens
and toxins. Once identified, potent and broadly neutralizing anti-
bodies could be used either as single agents or as a cocktail in
order to minimize the selection of escape mutants. One shouldconsider that in vitro neutralization assays do not fully reflect
the in vivo usefulness of antibodies because this may critically
depend on effector mechanisms such as complement- or
Fc receptor-mediated killing. Experimental infection of mice
carrying human Fc receptors may therefore be used to address
the in vivo activity of human monoclonal antibodies (Nimmerjahn
and Ravetch, 2008).
Another potential use of human monoclonal antibodies is their
administration together with a vaccine to enhance or modulate
the immune response. Antibodies can increase antigen uptake
by targeting immune complexes to Fc receptors expressed by
DCs leading to enhanced antigen presentation on MHC class I
and II molecules and modulation of the epitopes presented.
Furthermore, antibodies can suppress or enhance B cell
responses to their target antigens by several hundred-fold
depending on isotype and stoichiometry (Heyman, 2000).
Thus, by combining antigens and antibodies, we can foresee
a convergence of active and passive vaccination.
Interrogation of Memory T Cells
and Reconstruction of the Immune Response
Dissecting memory T cell subsets, rather than being a trivial
pursuit, has revealed fundamental aspects of the immune
response relevant for vaccine design. As discussed above, intra-
cellular pathogens, extracellular pathogens, and parasites elicit
effector and memory T cells with different functional properties.
Thus it is important that vaccines are designed to exploit the
full range of effector functions that are characteristic of protec-
tive responses (Sallusto and Lanzavecchia, 2009). Although
vaccines made by attenuated pathogens may carry the same
PAMPS or elicit the same DAMPS as the virulent pathogens
and thus may be able to induce the same type of response, indi-
vidual antigens taken out of their context and used as recombi-
nant proteins or inserted in heterologous vectors will critically
require adjuvants capable of eliciting the appropriate type of
immune response. Two experimental approaches can help to
address these issues: (1) the high throughput interrogation of
memory T cells and (2) the reconstruction of the immune
response in vitro (Figure 4).
Several methodologies are available to characterize at the
single-cell level the antigenic specificity, cytokine profile, homing
receptors, and functional properties of human memory T cellsImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 459
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tetramers, antibodies to surface molecules, cytokines, and
phospho-epitopes (Newell et al., 2009; Perez and Nolan, 2006).
This analysis can be combined with global gene profiling that
provides specific signatures of immune responses (Berry et al.,
2010; Querec et al., 2009). An alternative approach that is suit-
able for the analysis of HLA class II-restricted T cell responses
to complex antigens, even whole pathogens, and is not limited
to a particular HLA molecule consists of the screening of T cell
libraries prepared from effector and memory T cell subsets
(Figure 4; Geiger et al., 2009). This approach is revealing a
remarkable compartmentalization of pathogen-specific memory
T cells in individual memory subsets (F.S., unpublished data).
In addition to the analysis of the memory pool, tetramers and
T cell libraries can be used also to interrogate the naive CD8
and CD4 repertoires (Geiger et al., 2009; Newell et al., 2009).
Taken together, the high throughput interrogations of human
naive and memory T cell repertoires offer on the one hand
the possibility of predicting antigenicity and identifying T cell
epitopes in complex pathogens and on the other to gain informa-
tion on the class of T cells elicited by a given pathogens, thus
providing two critical pieces of information that should guide
T cell vaccine design.
An ambitious goal is currently to reconstruct in vitro the T and
B cell response to a pathogen (Figure 4). Although this may
eventually require the development of organotypic 3D cultures
(Ma et al., 2010), the priming of CD4 naive T cells can be
effectively achieved by coculture with APC and pathogens
(F.S. and C. Zielinsky, unpublished data). These in vitro priming
experiments can be used to identify polarizing cues in complex
pathogens and to dissect the signals and mechanisms of T cell
polarization, whichmay help in defining the right type of adjuvant
to be used in T cell vaccines.Concluding Remarks
The many recent advances in our understanding of the immune
system and the parallel development of various vectors and
adjuvants has now set the stage where the principles of immuno-
logical memory can be used to rationally design the next
generation of vaccines against infectious diseases of global
importance. In addition it should also be possible to learn from
our increasing understanding of T cell dysfunction during chronic
viral infections and tumors to develop therapeutic vaccines
against chronic diseases and cancers. There is growing con-
sensus in the immunological community that there is an urgent
need for new initiatives to strengthen research of the human
immune system (Germain, 2010, this issue) and to bridge the
fields of basic immunology and vaccine research.ACKNOWLEDGMENTS
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